Tags

Type your tag names separated by a space and hit enter

Herpes zoster virus vaccine.
Geriatrics. 2008 Oct; 63(10):6-9.G

Abstract

Varicella zoster virus (VZV) is the etiologic agent of varicella and herpes zoster (HZ) in humans. Herpes zoster is the result of reactivation of VZV within certain sensory ganglia. The burden of illness from HZ and post-herpetic neuralgia (PHN) is high. Herpes-zoster vaccine contains live attenuated varicella-zoster virus in an amount approximately 14 times greater than that found in the varicella virus vaccine. Herpes zoster vaccine is approved for the prevention of shingles in appropriate persons aged 60 and older. The vaccine is administered in a single subcutaneous dose. Reported side effects are mild and generally limited to localized injection site findings. Herpes-zoster vaccine reportedly decreases the occurrence of herpes zoster by approximately 50 percent and prevents the development of PHN by two thirds. The vaccine appears to be minimally effective in those individuals over the age of 80 and is not recommended in this age group.

Authors+Show Affiliations

Department of Family and Community Medicine, School of Medicine, Mercer University, Macon, GA, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18828650

Citation

Woolery, William Alan. "Herpes Zoster Virus Vaccine." Geriatrics, vol. 63, no. 10, 2008, pp. 6-9.
Woolery WA. Herpes zoster virus vaccine. Geriatrics. 2008;63(10):6-9.
Woolery, W. A. (2008). Herpes zoster virus vaccine. Geriatrics, 63(10), 6-9.
Woolery WA. Herpes Zoster Virus Vaccine. Geriatrics. 2008;63(10):6-9. PubMed PMID: 18828650.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Herpes zoster virus vaccine. A1 - Woolery,William Alan, PY - 2008/10/3/pubmed PY - 2008/10/22/medline PY - 2008/10/3/entrez SP - 6 EP - 9 JF - Geriatrics JO - Geriatrics VL - 63 IS - 10 N2 - Varicella zoster virus (VZV) is the etiologic agent of varicella and herpes zoster (HZ) in humans. Herpes zoster is the result of reactivation of VZV within certain sensory ganglia. The burden of illness from HZ and post-herpetic neuralgia (PHN) is high. Herpes-zoster vaccine contains live attenuated varicella-zoster virus in an amount approximately 14 times greater than that found in the varicella virus vaccine. Herpes zoster vaccine is approved for the prevention of shingles in appropriate persons aged 60 and older. The vaccine is administered in a single subcutaneous dose. Reported side effects are mild and generally limited to localized injection site findings. Herpes-zoster vaccine reportedly decreases the occurrence of herpes zoster by approximately 50 percent and prevents the development of PHN by two thirds. The vaccine appears to be minimally effective in those individuals over the age of 80 and is not recommended in this age group. SN - 1936-5764 UR - https://www.unboundmedicine.com/medline/citation/18828650/Herpes_zoster_virus_vaccine_ L2 - https://medlineplus.gov/shingles.html DB - PRIME DP - Unbound Medicine ER -